Valvular & structural heart disease
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers After Transcatheter Aortic Valve Replacement: A Meta-Analysis
Pooled result · All-cause mortalityResult — go to the resultRelative risk 0.74 95% CI 0.65–0.86Authors' conclusion
We found that patients receiving ACEIs/ARBs had a lower risk of all-cause mortality, cardiovascular mortality, and new-onset atrial fibrillation. Risk of other outcomes was similar to patients not receiving ACEIs/ARBs.
Study context
- Population
- Patients after transcatheter aortic valve replacement (TAVR)10 studies
- Comparison
- ACEi/ARB vs no ACEi/ARB after TAVR
- Outcome
- All-cause mortality
Methodological detailsrandom effects model, Literature search of PubMed and Cochrane Library until June 14, 2023
- Random effects model
- Literature search of PubMed and Cochrane Library until June 14, 2023
Pooled result
As reported in the abstract
Relative risk
0.74
95% CI 0.65–0.86
P < 0.01
ACEIs/ARBsvs No ACEIs/ARBs
RR 0.74 (95% CI 0.65–0.86); P < 0.01
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| CV mortalityI2 = 0%; chi-square (heterogeneity) P | 0.70 (0.56–0.88) | P = 0.54 | |
| New-onset AFI2 = 0%; chi-square (heterogeneity) P | 0.71 (0.52–0.96) | P = 0.59 | |
| 0.512Relative risk (log scale) |
MI, HF, stroke, new permanent pacemaker, aortic regurgitation, mitral regurgitation
- Similar risk with angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)
Safety
AKI, major bleeding, vascular complications
- Similar risk with ACEIs/ARBs
Original publication
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers After Transcatheter Aortic Valve Replacement: A Meta-Analysis. JACC Adv. Published 6 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →